NATR trades 83.9% below Wall Street's consensus target of $37.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NATR achieves its forward estimates and maintains a stable P/E multiple of 16.7x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Nature's Sunshine Products, Inc. (NATR) has a Wall Street consensus price target of $37.00, based on estimates from 4 covering analysts. With the stock currently trading at $20.12, this represents a potential upside of +83.9%. The company has a market capitalization of $354M.
Analyst price targets range from a low of $37.00 to a high of $37.00, representing a 0% spread in expectations. The median target of $37.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NATR trades at a trailing P/E of 19.0x and forward P/E of 16.7x. Analysts expect EPS to grow +8.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $22.96, with bear and bull scenarios of $14.46 and $30.25 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
USNAUSANA Health Sciences, Inc. | $348M | $18.88 | $35.00 | +85.4% | Hold | 10.9x | 8 |
NUSNu Skin Enterprises, Inc. | $244M | $5.02 | $11.00 | +119.1% | Hold | 5.0x | 11 |
NHTCNatural Health Trends Corp. | $20M | $1.82 | — | — | — | — | — |
MTEXMannatech, Incorporated | $10M | $5.42 | — | — | — | — | — |
HLFHerbalife Nutrition Ltd. | $1.2B | $11.90 | $18.50 | +55.5% | Buy | 4.5x | 26 |
PLBYPlayboy, Inc. | $135M | $1.45 | $12.63 | +771.0% | Buy | — | 8 |
AGENAgenus Inc. | $125M | $3.00 | $7.33 | +144.3% | Buy | 3.8x | 11 |
NBIXNeurocrine Biosciences, Inc. | $15.9B | $158.29 | $186.31 | +17.7% | Buy | 20.7x | 37 |
AMZNAmazon.com, Inc. | $2.6T | $244.39 | $307.77 | +25.9% | Buy | 27.8x | 94 |
WMTWalmart Inc. | $934.0B | $117.18 | $139.44 | +19.0% | Buy | 40.3x | 66 |
Quick answers to the most common questions about buying NATR stock.
The consensus Wall Street price target for NATR is $37, representing 83.9% upside from the current price of $20.12. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NATR has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $37 implies 83.9% upside from current levels.
With a forward P/E of 16.6971x, NATR trades at a relatively low valuation. The consensus target of $37 implies 83.9% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $37 for NATR, while the most conservative target is $37. The consensus of $37 represents the median expectation. Our quantitative valuation model projects a bull case target of $30 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
NATR is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NATR stock forecast based on 4 Wall Street analysts shows a consensus price target of $37, with estimates ranging from $37 (bear case) to $37 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $23, with bear/bull scenarios of $14/$30.
Our quantitative valuation model calculates NATR's fair value at $23 (base case), with a bear case of $14 and bull case of $30. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
NATR trades at a forward P/E ratio of 16.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 19.0x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on NATR, with a "Buy" consensus rating and $37 price target (83.9% upside). 2 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NATR analyst price targets range from $37 to $37, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $37 consensus represents the middle ground. Our model's $14-$30 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.